Astra Posts Solid U.S. Phase 3 Data for Vaccine
The wide-moat firm's vaccine showed a solid 79% efficacy level in preventing symptomatic COVID-19, which was better than we had expected.
AstraZeneca (AZN) reported strong U.S. phase 3 data for its COVID-19 vaccine, AZD1222. We don’t expect any changes to our fair value estimate based on the favorable data, however, since the firm plans to sell the vaccine on a not-for-profit basis. Nevertheless, the strong data and fast development timeline should help build goodwill with governments that could be helpful in keeping overall drug pricing policies stable, which is a key assumption in our wide moat rating.
In the phase 3 study, Astra’s vaccine showed a solid 79% efficacy level in preventing symptomatic COVID-19, which was better than we had expected. Prior phase 3 trials conducted outside the United States saw average efficacy around 67%, a number that was boosted by some patients receiving two doses with a wider time interval than in the U.S. study, so we had expected lower efficacy in the U.S. trial. While cross-trial comparisons carry several drawbacks, AZD1222 looks potentially more effective than Johnson & Johnson’s one-dose vaccine, which showed 72% efficacy in U.S. volunteers and 67% efficacy overall, but less effective than those of Pfizer/BioNTech and Moderna, which were both close to 95% efficacy. Importantly, though, the Astra vaccine showed 100% protection against severe disease in the trial and also showed strong efficacy in elderly volunteers. Complicating comparisons is the rise in variants of COVID-19, which may have weighed more heavily on Astra’s trial due to its recency, although the most worrisome South Africa variant was likely not seen, at least in large numbers, in this largely U.S.-based trial. With clinical development delays last year due to potential side effects and some European nations recently halting emergency use of Astra’s vaccine (for a short period) partly due to blood clotting issues, safety concerns have mounted around Astra’s vaccine, but the phase 3 data should offer some reassurance.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.